Axel Mark Inc.
Notice Regarding Change of Representative Director
With the growth strategy in the healthcare sector stagnating, a change of representative director was decided. The new Representative Director will be Tatsuya Saka (Representative Director of medical corporations, etc.), and the current Representative Director will resign and become a director. The change will take effect on September 17, 2026, with no impact on the consolidated results for the fiscal year ending September 2026.
Key Figures
- Change date: September 17, 2026
- New Representative Director: Tatsuya Saka (Representative Director of Medical Corporation Shikijōkai)
- Current position change: Hirofumi Matsukawa, President & Representative Director → Director
AI要約
Section Heading
This release reports the transition to a new management structure through the change of Representative Director, set against a backdrop of prolonged operating losses and stagnation in the growth strategy within the healthcare sector. The new Representative Director is appointed as Tatsuya Saka, with plans to rebuild the healthcare sector, including the existing Beauty & Wellness business, and to promote business investment. The current Representative Director, Hirofumi Matsukawa, will resign and participate in management as a director. The change will take effect on September 17, 2026.
Section 2 Heading
Looking ahead, the company states that the change will not directly affect the consolidated results for the fiscal year ending September 2026, and that rebuilding the growth strategy in the healthcare sector and achieving profitability in existing businesses may require a considerable period. The specific execution plans under the new structure and market reaction are uncertain, and the company will strive to restore the trust of shareholders and stakeholders with full effort.
Axel Mark Inc.
Company overview · Stock price · Financial data · All IR
